Cargando…

The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study

OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhi-Qiang, Feng, Xu-Dong, Ge, Chun-Lei, Yang, Yi, Liang, Na, Ye, Qing, Fu, Yang, Wei, Jian, Zhang, Yong, Li, Rong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673321/
https://www.ncbi.nlm.nih.gov/pubmed/36397078
http://dx.doi.org/10.1186/s13014-022-02158-4
_version_ 1784832919880073216
author Wang, Zhi-Qiang
Feng, Xu-Dong
Ge, Chun-Lei
Yang, Yi
Liang, Na
Ye, Qing
Fu, Yang
Wei, Jian
Zhang, Yong
Li, Rong-Qing
author_facet Wang, Zhi-Qiang
Feng, Xu-Dong
Ge, Chun-Lei
Yang, Yi
Liang, Na
Ye, Qing
Fu, Yang
Wei, Jian
Zhang, Yong
Li, Rong-Qing
author_sort Wang, Zhi-Qiang
collection PubMed
description OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwent taxane combined platinum-based concurrent chemoradiotherapy in our center between January 2013 and December 2018. All statistical analyses were performed using the Kaplan–Meier method (SPSS 23.0). Different groups were compared with the Wilcoxon rank-sum test. RESULTS: Ultimately, 104 patients were selected for this study, including 18 and 86 who received either concurrent chemoradiation therapy alone or concurrent chemoradiation therapy plus adjuvant chemotherapy, respectively. The median follow-up time for progression free survival was 53.0 months (IQR 48.5–57.5). The 3-years progression-free survival (PFS), overall survival (OS), local–regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates of the doublet regimen of concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma were 85.9%, 96.0%, 96.0% and 90.8%, respectively. Additionally, we analyzed the subgroups and found that the 3-years PFS, OS, LRRFS and DMFS rates for stage III versus stage IVa were 97.8% versus 75.5% (P = 0.000), 100% versus 92.5% (P = 0.004), 100% versus 92.4% (P = 0.015) and 97.8% versus 82.8% (P = 0.002), respectively. During concurrent chemotherapy, acute chemotherapy adverse events of grade 3 or 4 was only 18.3%. Leukopenia was the most common acute chemotherapy adverse event (in 10 patients [9.6%]), followed by neutropenia (in 8 patients [7.6%]). CONCLUSION: The doublet regimen of taxane plus platinum concurrent chemoradiotherapy resulted in improved long-term survival of locoregionally advanced nasopharyngeal carcinoma patients, especially for local control rate and warrants further prospective evaluation.
format Online
Article
Text
id pubmed-9673321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96733212022-11-19 The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study Wang, Zhi-Qiang Feng, Xu-Dong Ge, Chun-Lei Yang, Yi Liang, Na Ye, Qing Fu, Yang Wei, Jian Zhang, Yong Li, Rong-Qing Radiat Oncol Research OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwent taxane combined platinum-based concurrent chemoradiotherapy in our center between January 2013 and December 2018. All statistical analyses were performed using the Kaplan–Meier method (SPSS 23.0). Different groups were compared with the Wilcoxon rank-sum test. RESULTS: Ultimately, 104 patients were selected for this study, including 18 and 86 who received either concurrent chemoradiation therapy alone or concurrent chemoradiation therapy plus adjuvant chemotherapy, respectively. The median follow-up time for progression free survival was 53.0 months (IQR 48.5–57.5). The 3-years progression-free survival (PFS), overall survival (OS), local–regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates of the doublet regimen of concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma were 85.9%, 96.0%, 96.0% and 90.8%, respectively. Additionally, we analyzed the subgroups and found that the 3-years PFS, OS, LRRFS and DMFS rates for stage III versus stage IVa were 97.8% versus 75.5% (P = 0.000), 100% versus 92.5% (P = 0.004), 100% versus 92.4% (P = 0.015) and 97.8% versus 82.8% (P = 0.002), respectively. During concurrent chemotherapy, acute chemotherapy adverse events of grade 3 or 4 was only 18.3%. Leukopenia was the most common acute chemotherapy adverse event (in 10 patients [9.6%]), followed by neutropenia (in 8 patients [7.6%]). CONCLUSION: The doublet regimen of taxane plus platinum concurrent chemoradiotherapy resulted in improved long-term survival of locoregionally advanced nasopharyngeal carcinoma patients, especially for local control rate and warrants further prospective evaluation. BioMed Central 2022-11-17 /pmc/articles/PMC9673321/ /pubmed/36397078 http://dx.doi.org/10.1186/s13014-022-02158-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Zhi-Qiang
Feng, Xu-Dong
Ge, Chun-Lei
Yang, Yi
Liang, Na
Ye, Qing
Fu, Yang
Wei, Jian
Zhang, Yong
Li, Rong-Qing
The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title_full The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title_fullStr The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title_full_unstemmed The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title_short The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
title_sort long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673321/
https://www.ncbi.nlm.nih.gov/pubmed/36397078
http://dx.doi.org/10.1186/s13014-022-02158-4
work_keys_str_mv AT wangzhiqiang thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT fengxudong thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT gechunlei thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT yangyi thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT liangna thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT yeqing thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT fuyang thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT weijian thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT zhangyong thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT lirongqing thelongtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT wangzhiqiang longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT fengxudong longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT gechunlei longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT yangyi longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT liangna longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT yeqing longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT fuyang longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT weijian longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT zhangyong longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy
AT lirongqing longtermsurvivalofthedoubletregimenofconcurrentchemoradiationtherapyforlocoregionallyadvancednasopharyngealcarcinomaaretrospectivestudy